Please use this identifier to cite or link to this item:
Title: Detection of cancer-specific peptides in prostate cancer using MHC tetramer technology
Keywords: tetramer, major histocompatibility, prostate cancer
Issue Date: 9-Jul-2007
Citation: CHONG KIAN TAI (2007-07-09). Detection of cancer-specific peptides in prostate cancer using MHC tetramer technology. ScholarBank@NUS Repository.
Abstract: In prostate cancer management, prostate specific antigen (PSA) is the most common serum marker used for diagnosis, prognosis and disease monitoring. However, it does not have high specificity or sensitivity because it is not prostate cancer specific. The PSA protein has antigenic sequences that induce T-cell responses. Amongst T-lymphocytes, CD4+ T cells are highly specific in recognition of peptide antigens presented by major histocompatibility complexes (MHC) class II molecules. The study quantifies CD4+ T cells that recognise specific prostate peptides using tetramer technology.MHC class II tetramers are soluble recombinant human leucocyte antigen (HLA) molecules that bind to specific peptide antigens. These molecules enable surrogate interactions with antigen-specific T-cell receptors, independent of the presence of antigen-presenting cells. Using these MHC class II tetramers, we analysed highly specific MHC class II-peptide antigen complexes to screen for new CD4+ T-cell responsive epitopes that can detect cancer-specific peptides in prostate cancer patients.
Appears in Collections:Master's Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Chong Kian Tai 2007.pdf1.82 MBAdobe PDF



Page view(s)

checked on Apr 25, 2019


checked on Apr 25, 2019

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.